Cytokinetics (NASDAQ:CYTK) Releases Earnings Results, Hits Expectations

Cytokinetics (NASDAQ:CYTK) posted its earnings results on Tuesday. The biopharmaceutical company reported ($1.67) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.67), FiscalAI reports. The firm had revenue of $19.36 million for the quarter, compared to analyst estimates of $8.52 million. During the same period in the prior year, the business posted ($1.36) EPS. The firm’s quarterly revenue was up 1112.5% compared to the same quarter last year.

Here are the key takeaways from Cytokinetics’ conference call:

• MYQORZO U.S. launch exceeded expectations in a partial quarter with $4.8M net product revenue, ~680 patients prescribed by quarter-end (1,100 through April), and >275 unique HCP prescribers, supporting early commercial momentum.
• Top-line results from ACACIA‑HCM (aficamten) met both co‑primary endpoints (KCCQ and peak VO2) with statistically significant treatment effects and no new safety signals, prompting plans to engage regulators and pursue a supplemental NDA for NHCM.
• Q1 net loss widened to $206M (vs. $161M year‑ago), cash and investments declined to ~$1.1B after ~$144M use in the quarter, and SG&A rose to $104.9M due to commercial launch costs, though full‑year expense guidance was maintained.
• Rapid global commercialization and regulatory progress — EU approval with a Germany launch planned in Q2, FDA acceptance of the MAPLE‑HCM sNDA (PDUFA 11/14/2026), plus ongoing MAA submissions (Switzerland, Canada) and partner progress in APAC — support international growth plans.

Cytokinetics Stock Performance

Shares of NASDAQ:CYTK traded up $11.04 during midday trading on Tuesday, hitting $77.09. 18,074,833 shares of the stock were exchanged, compared to its average volume of 1,670,310. The stock has a market capitalization of $9.58 billion, a price-to-earnings ratio of -11.81 and a beta of 0.38. The business’s 50-day moving average price is $64.00 and its 200 day moving average price is $63.63. Cytokinetics has a 12 month low of $29.31 and a 12 month high of $80.20.

Analyst Ratings Changes

CYTK has been the subject of a number of research reports. Wells Fargo & Company initiated coverage on Cytokinetics in a report on Friday, April 10th. They set an “overweight” rating and a $95.00 target price for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Cytokinetics in a report on Monday, April 20th. Citizens Jmp lifted their target price on Cytokinetics from $88.00 to $96.00 and gave the stock a “market outperform” rating in a report on Wednesday, February 25th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $90.00 price target on shares of Cytokinetics in a research note on Friday, January 9th. Finally, Morgan Stanley set a $90.00 price target on Cytokinetics in a research note on Thursday, January 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $92.10.

Key Stories Impacting Cytokinetics

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: Topline Phase‑3 win — the ACACIA‑HCM pivotal trial of aficamten met both dual primary endpoints with supportive secondary data, a major de‑risking event that expands the drug’s commercial and regulatory potential. ACACIA‑HCM Topline Results
• Positive Sentiment: Strong initial commercial uptake — management reported U.S. launch demand for MYQORZO with ~275 HCPs prescribing to an estimated ~680 patients in Q1 and ~$4.8M in partial‑quarter net product revenue; company also reported ~ $1.1B in cash, which supports launch and development. Q1 2026 Financial Results & Business Update
• Positive Sentiment: Analyst upgrades — Needham (and other firms) raised price targets, increasing buy‑side enthusiasm and providing upward analyst momentum for shares. Analyst Price Target Raises
• Neutral Sentiment: Q1 reported EPS loss of ($1.67) matched expectations while revenue materially beat consensus ($19.36M vs ~$8.5M), signaling revenue strength but continued GAAP losses as the company scales launch and development. Q1 Loss, Revenue Beat
• Neutral Sentiment: Insider sales disclosed — EVP Andrew Callos and EVP Fady Malik sold shares under pre‑arranged Rule 10b5‑1 plans (large planned disposals rather than ad‑hoc exits); commonly viewed as neutral but can prompt short‑term investor attention. Malik SEC Form 4 Callos SEC Form 4
• Negative Sentiment: Planned $650M underwritten common stock offering — while proceeds would fund commercialization and development, the offering presents near‑term dilution risk that can weigh on the share price until completed. Proposed Public Offering

Insider Transactions at Cytokinetics

In other Cytokinetics news, CEO Robert I. Blum sold 7,500 shares of the company’s stock in a transaction dated Wednesday, April 29th. The stock was sold at an average price of $59.62, for a total value of $447,150.00. Following the sale, the chief executive officer owned 407,830 shares in the company, valued at approximately $24,314,824.60. The trade was a 1.81% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Andrew Callos sold 15,857 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $65.00, for a total value of $1,030,705.00. Following the completion of the sale, the executive vice president owned 58,555 shares in the company, valued at $3,806,075. The trade was a 21.31% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 184,976 shares of company stock worth $11,639,319. Insiders own 2.60% of the company’s stock.

Institutional Trading of Cytokinetics

Several institutional investors have recently added to or reduced their stakes in the stock. State Street Corp boosted its holdings in Cytokinetics by 3.7% in the fourth quarter. State Street Corp now owns 5,825,295 shares of the biopharmaceutical company’s stock valued at $370,139,000 after acquiring an additional 207,961 shares during the last quarter. Deep Track Capital LP boosted its holdings in Cytokinetics by 17.8% in the third quarter. Deep Track Capital LP now owns 4,300,000 shares of the biopharmaceutical company’s stock valued at $236,328,000 after acquiring an additional 650,000 shares during the last quarter. Vestal Point Capital LP boosted its holdings in Cytokinetics by 14.8% in the second quarter. Vestal Point Capital LP now owns 2,975,000 shares of the biopharmaceutical company’s stock valued at $98,294,000 after acquiring an additional 384,469 shares during the last quarter. Woodline Partners LP boosted its holdings in Cytokinetics by 676.1% in the third quarter. Woodline Partners LP now owns 1,647,725 shares of the biopharmaceutical company’s stock valued at $90,559,000 after acquiring an additional 1,435,422 shares during the last quarter. Finally, Northern Trust Corp boosted its holdings in Cytokinetics by 2.0% in the third quarter. Northern Trust Corp now owns 1,406,832 shares of the biopharmaceutical company’s stock valued at $77,319,000 after acquiring an additional 27,641 shares during the last quarter.

Cytokinetics Company Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.